Request Demo

Last update 23 Jan 2025

Tretinoin

Last update 23 Jan 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryVesanoid, also known as Tretinoin, is a vitamin A derivative that has been given the green light for treating acne vulgaris and specific forms of promyelocytic leukemia. This drug, originating from the pharmaceutical company Bausch Health Americas, acts as a RARs agonist that helps regulate gene expression and cell differentiation in a multifaceted manner, displaying a higher level of complexity in its mechanism of action. With its initial approval in the United States in 1971, Tretinoin has been increasingly incorporated into numerous over-the-counter products, due to its demonstrated efficacy in managing a wide range of skin conditions. Because of its reliability in the management of acne vulgaris, Tretinoin has gained widespread popularity among dermatologists and individuals seeking to alleviate this all-too-common skin condition. Its continued use in contemporary medicine reinforces Tretinoin's value as a valuable weapon in the struggle against acne and other cutaneous disorders, lending credence to its ongoing utility.

Drug Type

Small molecule drug

Synonyms

(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL), ATRA

+ [40]

Target

RARs

Mechanism

RARs agonists(Retinoic acid receptors agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [7]

Active Indication

Facial wrinklesAcute Promyelocytic LeukemiaAcne Vulgaris+ [5]

Inactive Indication

MelanosisOnycholysisPhotosensitivity Disorders+ [1]

Originator Organization

Bausch Health Americas, Inc.

Active Organization

Genentech, Inc.Valeant International (Barbados) SRLBausch Health US LLC

+ [7]

Inactive Organization

Azidus BrasilBausch Health Americas, Inc.

Spear Pharmaceuticals, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

US (20 Oct 1971),

Acne Vulgaris

RegulationOrphan Drug (JP)

Structure/Sequence

Molecular FormulaC20H28O2

InChIKeySHGAZHPCJJPHSC-YCNIQYBTSA-N

CAS Registry302-79-4

257

Clinical Trials associated with Tretinoin

NCT06528769

/ Not yet recruitingPhase 2IIT

A Phase II Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients with Advanced Leiomyosarcoma

A phase 2 study assessing the efficacy of all-trans retinoic acid (ATRA) and Cemiplimab in patients with metastatic/locally advanced - unresectable leiomyosarcoma (LMS) who have progressed standard-of-care therapy. Patients will be enrolled in cohorts according to a Bayesian Optimal Phase II design (BOP2).
Study treatment will consist of ATRA at a starting dose of 150 mg/m2/day for 3 days orally prior to each cycle of Cemiplimab 350 mg IV q3 weeks for three cycles and then Cemiplimab monotherapy until the progress of disease or unacceptable toxicities develops.

Start Date01 Apr 2025

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

NCT06706401

/ Not yet recruitingPhase 3IIT

A Multicenter, Randomised 2*2 Factorial Design Comparing Standard to Reduced-target Volume Radiotherapy With or Without All-trans Retinoic Acid (ATRA) in Patients With Lateralised Oropharyngeal, Laryngeal and Hypopharyngeal Squamous Cell Carcinoma.

The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.

Start Date01 Jan 2025

Sponsor / Collaborator

Centre Léon Bérard Lyon et Rhône-Alpes

ChiCTR2400093990

/ SuspendedNot ApplicableIIT

Neoadjuvant treatment with all-transretinoic acid combined with PD-1inhibitors and platinum-containing double-drug chemotherapy can resect stage ? and single-arm stage? non-small-cell lung cancer:aclinical study.

Start Date20 Dec 2024

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

100 Clinical Results associated with Tretinoin

100 Translational Medicine associated with Tretinoin

100 Patents (Medical) associated with Tretinoin

24,339

Literatures (Medical) associated with Tretinoin

01 Mar 2025·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

The intestine-specific homeobox (ISX) modulates β-carotene-dependent regulation of microsomal triglyceride transfer protein (MTP) in a tissue-specific manner

Article

Author: Quadro, Loredana ; Hammerling, Ulrich ; Kim, Youn-Kyung ; Hussain, M Mahmood ; Champaneri, Dhruv ; Giordano, Elena ; von Lintig, Johannes

Vitamin A is an essential nutrient crucial to ensuring proper mammalian embryonic development. β-Carotene is the most prevalent form of vitamin A in food that, when transferred in its intact form from mother to the developing tissues, can serve as an in situ source of retinoic acid, the active form of vitamin A. We have previously provided evidence that the maternal-fetal transfer of β-carotene across the placenta is mediated by lipoproteins and that β-carotene itself regulates placenta lipoprotein biogenesis by means of its derivatives β-apo-10'-carotenoids and retinoic acid. These metabolites exert antagonistic transcriptional activity on placental microsomal triglyceride transfer protein (MTP) and apolipoprotein B (APOB), two key players of lipoprotein biosynthesis. Here, we analyzed the time-dependency of this regulation over the course of 24 h upon a single maternal administration of β-carotene. We also tested the hypothesis that the transcriptional repressor intestine-specific homeobox (ISX) plays a role in the regulation of Mttp in placenta. We observed that ISX is expressed in placenta of mouse dams and is regulated by β-carotene availability. Furthermore, we demonstrated that the absence of Isx disrupts the β-carotene-mediated regulation of placental MTP. We also showed that this mechanism is organ-specific, as it was not observed in enterocytes of the intestine, a major place of Isx expression. Therefore, we identified ISX as a "master" regulator of a placental β-carotene-dependent transcriptional regulatory cascade that fine-tunes the flux of provitamin A carotenoid towards the developing fetus.

01 Mar 2025·Mitochondrion

Reactive oxygen species favors Varicellovirus bovinealpha 5 (BoAHV-5) replication in neural cells

Article

Author: Rodríguez, Marcelo ; Pérez, Sandra ; Marin, Maia ; Brunner, María Belén ; Maldonado, Eduardo Néstor ; Rosales, Juan José

Varicellovirus bovinealpha (BoAHV) 1 and 5 are closely related neurotropic alphaherpesviruses with distinct neuropathogenic potential. BoAHV-5 causes meningoencephalitis in calves whereas encephalitis by BoAHV-1 infection is sporadic. the mechanisms underlying the differences in tropism and clinical outcomes of the infections are not yet completely understood. Here, we used neuroblastoma SH-SY5Y cells as non-differentiated in comparison with the SH-SY5Y neuronal-like cells obtained after exposing SH-SY5Y undifferentiated cells to trans-retinoic acid. We aimed to establish whether there was a relationship between the production of reactive oxygen species (ROS) and the kinetics of virus replication. We demonstrated that ROS production after BoAHV infection was higher in differentiated cells. Generation of ROS was also dependent on the infecting BoAHV strain. Higher ROS levels were produced during BoAHV-5 infection concomitantly with enhanced viral replication. We propose that increased ROS production mechanistically contributes to the tissue damage and neuroinflammation induced by BoAHV-5 infection. Future studies will determine specific targets of ROS that mediate the effects on viral replication.

01 Mar 2025·Recent Patents on Nanotechnology

An Efficient Suppression of EGFR and B-Raf mRNA Overexpression in the Lung of Benzo[a]pyrene-induced mice by Cationic Lipo-ATRA Nanoformulation

Article

Author: Singaram, Viswanathan ; Wilson Devarajan, David ; Chandrasekharan, Guruvayoorappan ; Mariammal, Berlin Grace Viswanathan ; Siddikuzzaman ; Ravichandran, Ragavi ; Chinnadurai, Kathirvelan

Background:The molecular drug all-trans retinoic acid (ATRA) acts on cancer cells via different molecular pathways, but its poor bioavailability in cancer cells limits its potency. This study was, therefore, carried out to analyse the oncogene expressions in the lung tissue of benzo[a]pyrene (B[a]P)-induced mice and compare between free ATRA and cationic liposome nanoformulation (lipo- ATRA) treatments.Objective:This study was designed to analyse the changes in the expression levels of epidermal growth factor receptor (EGFR) and B-Raf in the lung tissues of B[a]P-induced mice during the cancer development stage itself and to find the suppressive effect of free ATRA and lipo-ATRA.Methods:Lung cancer was induced in mice by oral ingestion of 50mg/kg body weight B[a]P weekly twice for four consecutive weeks. Then, the mice were treated with free and lipo-ATRA (0.60mg/kg) for 30 days via i.v injection. The EGFR and B-Raf gene expressions were analyzed in lung cells by reverse transcriptase polymerase chain reaction (RT-PCR) and quantitative polymerase chain reaction (qPCR).Results:The RT-PCR gene band density and the relative quantity (RQ) values from qPCR revealed both EGFR and B-Raf genes to be significantly overexpressed in B[a]P control mice while having very low or no expression in normal mice. This indicates that they function as oncogenes in B[a]P-induced lung carcinogenesis. The lipo-ATRA treatment has shown a highly significant increase in RQ values for both EGFR and BRaf when compared to the free ATRA treatment.Conclusion:The study results have revealed the cationic lipo-ATRA treatment to have enhanced the bioavailability of ATRA in lung tissue due to its significant suppression action on EGFR-mediated oncogenes’ expressions. Furthermore, the EGFR and BRaf could be the molecular targets of ATRA action in lung carcinogenesis.

News (Medical) associated with Tretinoin

16 Jan 2025

·endpts.com

FDA rejects Atara's cell therapy for rare transplant complication, stock craters

US regulators have rejected a T cell therapy for a rare and serious transplant complication related to Epstein-Barr virus from Atara Biotherapeutics and Pierre Fabre. The therapy, known as tabelecleucel or tab-cel, was turned away after the FDA inspected a third-party manufacturing site, Atara said in a Thursday press release . FDA’s rejection letter “did not identify any deficiencies” related to the manufacturing of the therapy itself, nor any concerns over efficacy or safety data, Atara said. Additionally, it will not be required to run another clinical trial. Atara’s stock price $ATRA fell more than 45% on Thursday morning. The company had been on shaky ground heading into Wednesday’s PDUFA date, and the rejection only adds to its worries. The company had been looking at “strategic alternatives” for the rest of its pipeline, but if it can’t find any additional funding by the end of the first quarter, it will halt development of everything except tab-cel and may transfer outstanding “operational activities” related to tab-cel to Pierre Fabre. The company had been slated to receive a $60 million milestone payment from Pierre Fabre alongside the approval, and is still eligible to receive it. Atara CEO Cokey Nguyen said in a statement that execs are working to resolve the issues and resubmit its application. Another decision would likely be slated for six months after resubmission. Atara also said it took out a loan of up to $15 million to get through the BLA resubmission. An acquisition, merger, reverse merger or other asset sales are also on the table, Atara said. Atara had been evaluating the treatment for patients 2 years and older with what’s called Epstein-Barr virus positive post-transplant lymphoproliferative disease (PTLD) who have received at least one prior therapy. People who receive transplants take medicine to suppress their immune systems, but in people with this rare complication, that can lead the virus to take hold and cause immune cells to grow out of control. There are no approved treatments in the US specifically for the disease, though it can be treated with the antibody rituximab or chemotherapy. Tab-cel already won approval in the EU in 2022 and the UK in 2023, and is branded as Ebvallo. The therapy developed by Atara is expected to be commercialized by Pierre Fabre. Tab-cel is an allogeneic T cell therapy that targets EBV-infected cells. The therapy was studied in a Phase 3 open-label trial called ALLELE, where it resulted in a 48.8% response rate in people with EBV+ PTLD after they tried either rituximab or rituximab plus chemotherapy.

Cell TherapyPhase 3Clinical ResultImmunotherapyAcquisition

15 Jan 2025

·www.globenewswire.com

Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare’s Landmark Report

VANCOUVER, British Columbia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is excited to announce that its cutting-edge anti-aging compound, TFC-1326, has been highlighted in Stonegate Healthcare Partners’ latest research report. The publication, titled "Sirona Biochem’s TFC-1326 Clinical Data Versus Retinoid Clinical Data," provides an extensive evaluation of TFC-1326’s clinical trial performance, setting it apart from traditional retinoid treatments. The report outlines the remarkable benefits of TFC-1326, including: Boosting skin radianceSignificantly reducing wrinkle depth and volumeEnhancing skin elasticity and firmnessEnsuring deep hydration with no irritation Stonegate Healthcare’s analysis underscores TFC-1326’s ability to deliver rapid, consistent results while also providing potent antioxidant and anti-inflammatory benefits. Unlike traditional retinoids, which can cause irritation, TFC-1326 is ideal for all skin types, including sensitive skin, redefining what’s possible in the $12.5 billion global anti-aging market. "This recognition by Stonegate Healthcare Partners highlights the transformative potential of TFC-1326," said Dr. Verrico, CEO of Sirona Biochem. "Our mission has always been to push the boundaries of skincare science, and we are proud to see our innovation recognized in this detailed analysis." The publication positions TFC-1326 as a disruptive force in cosmetic dermatology, offering a highly effective, user-friendly alternative to conventional treatments. This achievement reflects Sirona Biochem’s ongoing commitment to pioneering advanced solutions in the skincare industry. Access the Full Report Here: https://shp.reportablenews.com/pr/stonegate-healthcare-research-update-on-sirona https://stonegateinc.com/download/stonegate-healthcare-partners-announces-publication-of-a-literature-review-on-anti-aging-dermatology/?wpdmdl=1269&refresh=677efef279b251736376050 About Sirona Biochem Sirona is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees, and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com. Forward Looking Statements This news release includes certain statements that may be deemed “forward-looking statements.” All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance, and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates, or opinions, or other factors, should change. Contact Information: Christopher HoptonChief Financial OfficerSirona Biochem Corp.Phone: (604) 641-4466Email: info@sironabiochem.comWebsite: www.sironabiochem.com

07 Jan 2025

·www.globenewswire.com

Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in acute promyelocytic leukemia (APL)The researchers reported that APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) classes of targeted therapies but that in about 13% of cases of APL, conventional cytogenetics fails to identify the variant(s) that indicate(s) these treatmentIdentification of this PML::RARA fusion variant by OGM is consistent with previously reported findings which show that OGM can detect variants found by standard cytogenetics and can also find additional variants that are missed by these techniques SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication from the Johns Hopkins University School of Medicine in Genes showing that optical genome mapping (OGM) identifies a variant in an aggressive form of acute myelogenous leukemia (AML) known as acute promyelocytic leukemia, or APL. This variant is often missed by conventional cytogenetic techniques. In the case study, researchers reported that OGM detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in APL. According to the publication, APL is a subtype of AML that responds well to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) classes of targeted therapies but that in about 13% of cases of APL, conventional cytogenetics either fails or is unable to clearly identify the variant(s) that indicate(s) these treatment(s). Notably, identification of this PML::RARA fusion variant by OGM is consistent with previously reported findings which show OGM can detect variants found by standard cytogenetics but can also find likely pathogenic variants that are missed or deemed uninterpretable by these techniques. Erik Holmlin, president and chief executive officer of Bionano, commented, “This case study supports the view that the standard of care techniques used for devastating diseases like blood cancer are insufficient to reliably guide therapy selection and patient management, due to their tendency to miss actionable variants for a significant fraction of cases. It also shows that OGM, with its higher resolution, streamlined workflow and ability to find more variants, can be a suitable alternative to these techniques, and could result in better therapy selection and patient management decisions.” The full research publication is available at: Optical Genome Mapping Reveals Complex and Cryptic Rearrangement Involving PML::RARA Fusion in Acute Promyelocytic Leukemia. About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit www.bionano.com or www.bionanolaboratories.com. Bionano’s products are for research use only and not for use in diagnostic procedures. Forward-Looking Statements of Bionano Genomics This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “ability,” “can,” “could,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s ability to detect variants undetected by traditional cytogenetic techniques; OGM’s ability to detect the PML::RARA fusion in acute promyelocytic leukemia (APL); the potential utility that variants detected by OGM may have in therapy selection or patient management decisions; the utility of OGM for uses described in the publication referenced in this press release; the utility and ability of OGM to detect variants missed by traditional cytogenetic techniques; and other statements that are not historical facts. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, supply chain disruptions, global pandemics, inflation, and the ongoing conflicts between Ukraine and Russian and Israel and Hamas, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the failure of OGM to detect variants undetected by traditional cytogenetic techniques; the failure of OGM to detect the PML::RARA fusion in acute promyelocytic leukemia (APL); the failure of OGM to prove useful in therapy selection or patient management decisions; the failure of OGM to be useful for the applications described in the publication referenced in this press release; the failure of OGM to detect variants missed by traditional cytogenetic techniques; future publications that contradict the findings of the publication referenced in this press release; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; our ability to effectively manage our uses of cash, and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com Investor Relations:David HolmesGilmartin Group+1 (858) 888-7625IR@bionano.com

Clinical ResultClinical Study

100 Deals associated with Tretinoin

External Link

KEGG	Wiki	ATC	Drug Bank
D00094	Tretinoin	D10AD01 L01XX14	DB00755

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Facial wrinkles	US	Bausch Health Cos., Inc.	31 Aug 2000
Acute Promyelocytic Leukemia	FR	CHEPLAPHARM Arzneimittel GmbH	05 Aug 1996
Acne Vulgaris	US	Valeant International (Barbados) SRL	20 Oct 1971
Psoriasis	CN	-	-
Skin Diseases	CN	-	-
Vitiligo	CN	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanosis	Phase 3	BR	Azidus Brasil	01 Jul 2008
Microsatellite Stable Colorectal Carcinoma	Phase 2	US	Genentech, Inc.	19 Dec 2023
Rosacea	Phase 1	US	Bausch Health Americas, Inc.	01 May 2010
Photosensitivity Disorders	Phase 1	US	Coria Laboratories Ltd.	01 Jan 2008
Acne Vulgaris	Phase 1	US	Mylan Pharmaceuticals, Inc.	29 Jan 1998
Behcet Syndrome	Discovery	DZ	University of Science & Technology	25 Jun 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05438875 (MSC-C5b-9, ASH2024)	Phase 3	Purpura, Thrombocytopenic, Idiopathic MSC-C5b-9-positive	96	Eltrombopag	(vgwwmvihzc) = xnrokictbc ovivewrnex (bpkdwndcsy )	Positive	09 Dec 2024
				Eltrombopag + ATRA	(vgwwmvihzc) = jseganaool ovivewrnex (bpkdwndcsy )
ASH2024	Not Applicable	Multiple Myeloma	-	All-Trans Retinoic Acid (MM cells)	lwmeizvkkj(hjxixitddu) = ngodmfmhmc myetjrllxc (ubnafyxsyr )	-	07 Dec 2024
NCT04305041 (KEYMAKER-U02A, ASCO2024) Manual	Phase 1/2	Melanoma	100	Pembrolizumab + Quavonlimab + Vibostolimab	(jseyasbzfl) = xkuxzdnxlx gdnbdqvmyb (jjvwpdazfx ) View more	Negative	24 May 2024
				Pembrolizumab + Quavonlimab + Lenvatinib	(jseyasbzfl) = ctdxtjcoyl gdnbdqvmyb (jjvwpdazfx ) View more
NCT05386823 (CTgov)	Phase 1	-	16	Placebo (Placebo)	fwcwwvbuzz(phopvjetny) = trpxlwzerz rlbsktmnkk (uhudhixnqa, zcspiuzseg - cotvktruvm) View more	-	23 May 2024
				HF1K16 (3 mg/m² HF1K16)	bhijpzukfb(ralbmmlydq) = wpdumwpqeh vuqmerrork (grqgxmyjtj, srrqmvmuyb - pcrwecdrqr) View more
NCT03572387 (CTgov)	Phase 2	Castration-Resistant Prostatic Cancer	14	ATRA+5-AZA ('Early' 5-AZA+ATRA)	hwcmhejnum(itpcjiezxb) = hwgrozxiwe yqxbsguhyi (tmvpurwywr, oygapwbgbo - swqhwhdcko) View more	-	30 Apr 2024
				ATRA+5-AZA ('Delayed' 5-AZA+ATRA)	hwcmhejnum(itpcjiezxb) = donishajva yqxbsguhyi (tmvpurwywr, fwoyrxnuqv - ajemwakgft) View more
AACR2024 Manual	Not Applicable	Prostatic Cancer	14	azacitidine+ ATRA)ATRA	(udepovogan) = The most common TRAEs included hot flashes, white blood cell decreased and lymphocyte count decreased (all 8.3% each), and anemia (5.6%) oilkzslshl (zyiagibket )	Positive	05 Apr 2024
ASH2023	Not Applicable	Acute Promyelocytic Leukemia	-	Oral-Arsenic Trioxide	(kzadbxtudg) = numaukbfbd iqczsmetwp (gihxkaimmt ) View more	-	09 Dec 2023
				All-Trans Retinoic Acid	(kzadbxtudg) = kvydhkdbfy iqczsmetwp (gihxkaimmt ) View more
ASH2023	Not Applicable	Acute Promyelocytic Leukemia	135	ATRA-ATO	(pwfavhvwzu) = spgvclrofr vdndkxpkuq (dqemllqmmk ) View more	Positive	09 Dec 2023
				ATRA+chemotherapy	(pwfavhvwzu) = otwgwnnpgm vdndkxpkuq (dqemllqmmk ) View more
P-192 (EORTC_CLTG2023)	Not Applicable	Mycosis Fungoides First line	211	Methotrexate monotherapy	iafbduxpms(gnszgclyir) = Therapy was discontinued in 14 (6.7%) cases due to drug intolerance ymlfaneakq (pwyccghbea ) View more	Positive	21 Sep 2023
				Methotrexate + phototherapy
AML-103 (SOHO2023)	Not Applicable	Acute Promyelocytic Leukemia Consolidation \| Maintenance	12	ATRA+ATO	erfdnjkknk(akwtilqvma) = figkjbabfl iyisgnbiqt (ziefnmxdmk )	Positive	01 Sep 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis